The estimated Net Worth of Life Sciences, Llc Platinum... is at least $2.63 Milión dollars as of 4 September 2012. Life Platinum owns over 708,382 units of Navidea Biopharmaceuticals Inc stock worth over $6,764 and over the last 12 years Life sold NAVB stock worth over $2,621,013.
Sign up
Life Platinum NAVB stock SEC Form 4 insiders trading
Life has made over 1 trades of the Navidea Biopharmaceuticals Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently Life sold 708,382 units of NAVB stock worth $2,621,013 on 4 September 2012.
The largest trade Life's ever made was selling 708,382 units of Navidea Biopharmaceuticals Inc stock on 4 September 2012 worth over $2,621,013. On average, Life trades about 354,191 units every 0 days since 2012. As of 4 September 2012 Life still owns at least 6,763,986 units of Navidea Biopharmaceuticals Inc stock.
You can see the complete history of Life Platinum stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Life Platinum's mailing address?
Life's mailing address filed with the SEC is 152 W. 57TH STREET,152 WEST 57TH STREET, 4TH FLOOR54TH FLOOR, NEW YORKNEW YORK, NYNY, 1001910019.
Insiders trading at Navidea Biopharmaceuticals Inc
Over the last 13 years, insiders at Navidea Biopharmaceuticals Inc have traded over $3,167,813 worth of Navidea Biopharmaceuticals Inc stock and bought 7,718,496 units worth $6,241,151 . The most active insiders traders include John K Jr. Scott, Perry A Karsen a Life Sciences, Llc Platinum.... On average, Navidea Biopharmaceuticals Inc executives and independent directors trade stock every 63 days with the average trade being worth of $159. The most recent stock trade was executed by John K Jr. Scott on 10 April 2022, trading 3,260 units of NAVB stock currently worth $3.
What does Navidea Biopharmaceuticals Inc do?
navidea biopharmaceuticals, inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. it operates through two segments, diagnostic substances and therapeutic development programs. the company develops manocept platform to target the cd206 mannose receptor expressed on activated macrophages. its cd206-targeted drug platform is applicable to a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (pet), imaging and topical gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. further, the company offers nav4694, a fluorine-18 labeled pet imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of alzheimer's disease and mild cognitive impairment. in addition, it is de
What does Navidea Biopharmaceuticals Inc's logo look like?
Complete history of Life Platinum stock trades at Navidea Biopharmaceuticals Inc
Navidea Biopharmaceuticals Inc executives and stock owners
Navidea Biopharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Jed Latkin,
Chief Executive Officer, Chief Financial Officer, Chief Operating Officer -
Dr. Michael Stanley Rosol Ph.D.,
Sr. VP & Chief Medical Officer -
Michael Rosol,
Chief Medical Officer -
Y. Michael Rice,
Independent Chairman of the Board -
S. Kathryn Rouan,
Independent Director -
Adam Cutler,
Independent Director -
Claudine Bruck,
Independent Director -
Dr. Michel Mikhail Ph.D.,
Chief Regulatory Officer -
Jeffrey Smith,
VP of Operations -
Joel Harrison Kaufman,
Chief Bus. Officer -
William J. Regan,
Chief Strategy Officer & Chief Compliance Officer -
Erika Gibson,
Director of Fin. & Admin. -
Alexander L Cappello,
Director -
Anthony S. Fiorino,
Director -
Mark I Greene,
Director -
Brent L Larson,
EVP, CFO, Treas and Secy -
Gordon A Troup,
Director -
Eric K Rowinsky,
Director -
Thomas J Klima,
SVP & Chief Commercial Ofc -
William J. Regan,
SVP-Global Regulatory Strategy -
Michael M Goldberg,
Director -
Frederick O Cope,
Senior VP and CSO -
John K Jr. Scott,
-
Life Sciences, Llc Platinum...,
-
Rodger A Brown,
Vice President -
Perry A Karsen,
Director -
Thomas H. Tulip,
President -
Mark Platinum Management (N...,
-
Brendan A Ford,
Director -
Mark Jerome Pykett,
Pres. & CEO -
Cornelia Reininger,
SVP & Chief Medical Officer -
Jess Jones,
Director -
Anton Gueth,
Director -
Dana J Moss,
-
Joel H. Kaufman,
Chief Business Officer -
Malcolm G Witter,
Director -
Amit Bhalla,
Director -
Michel Mikhail,
Chief Regulatory Officer -
Agnieszka Winkler,
Director -
Thomas F Farb,
Director -
Joshua M. Wilson,
Director -
Jill Stefanelli,
-
Craig Dais,
CHIEF FINANCIAL OFFICER